Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug

Patent metadata

Field	Value
Publication number	US-9750734-B2
Application number	US-201414907221-A
Country	US
Kind code	B2
Filing date	Jul 24, 2014
Priority date	Jul 24, 2013
Publication date	Sep 5, 2017
Grant date	Sep 5, 2017

Abstract

The present invention relates to the use of flecainide as an anti-connexin agent. This anti-connexin agent is advantageously used to potentiate the therapeutic effect of various psychotropic drugs. More specifically, the invention provides a combination product containing flecainide and modafinil.

First claim

The invention claimed is:

1. A therapeutic composition comprising flecainide and at least one psychotropic drug, wherein said at least one psychotropic drug is modafinil.

2. A method for treating fatigue, somnolence, or sleepiness in an individual in need thereof comprising administration of the therapeutic composition according to claim 1 to said individual.

3. A method for at least one of enhancing the memory of healthy subjects or maintaining said healthy subjects awake for long-lasting periods of time comprising administration of the therapeutic composition of claim 1 to said healthy subjects.

4. A method for treating cataplexy in a narcoleptic patient comprising administration of the therapeutic composition according to claim 1 to said narcoleptic patient.

5. The therapeutic composition of claim 1 , wherein said flecainide is the R enantiomer of formula:

6. A method for enhancing the memory of healthy subjects and/or for maintaining them awake for long-lasting periods of time comprising the administration to said healthy subjects of a) flecainide and b) modafinil, in which said compounds a) and b) are administered simultaneously, separately or in a staggered manner.

7. The method of claim 2 , wherein said flecainide is the R enantiomer of formula:

8. A method for potentiating the effects of modafinil, comprising the administration of flecainide as an anti-connexin agent.

9. The method of claim 8 , wherein potentiating the effects of modafinil further comprises potentiating the promnesiant effect and/or the awakening effect of modafinil.

10. The method of claim 8 , wherein said flecainide is the R enantiomer of formula:

11. The method of claim 2 , wherein said flecainide in said therapeutic composition is the R enantiomer of formula:

12. The method of claim 3 , wherein said flecainide in said therapeutic composition is the R enantiomer of formula:

13. The method of claim 4 , wherein said flecainide in said therapeutic composition is the R enantiomer of formula:

14. The method of claim 6 , wherein said flecainide is the R enantiomer of formula:

15. The method of claim 8 , wherein potentiating the effects of modafinil further comprises increasing at least one of the efficacy, safety, or duration of the action of modafinil.

16. The method of claim 15 , wherein said flecainide is the R enantiomer of formula:

17. The method of claim 9 , wherein said flecainide is the R enantiomer of formula:

18. The method of claim 2 wherein the individual is suffering from excessive daytime sleepiness (EDS), sleep disorders, insufficient sleep time, central sleep apnea, narcolepsy with cataplexy, narcolepsy without cataplexy, obstructive sleep apnea/hypopnea (SAHOS), idiopathic hypersomnia, Kleine-Levin syndrome, circadian rhythm disorders, shift work sleep disorder, jet-lag, disorders after sleep restriction or sleep deprivation, attention disorders, alertness disorders, insomnia, parasomnia, medical-induced somnolence, restless legs syndrome (RLS), Periodic Lim Movement Disorders (PLMD), attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), Parkinson disease, multiple sclerosis, stroke, neuromuscular disorders, structural brain disorders, respiratory disorders, chronic renal failure, liver failure, rheumatologic disorders, mood disorders, anxiety disorders, schizophrenia, tinnitus, depression, malaise, dementia, bipolar disorder, obesity, hyperphagia, manic episode, obsessive-compulsive disorder, senility, dependence or addiction, cancer, neurodegenerative disorders, menopause, traumatic brain injuries, viral infection or post-myelitis, or fibromyalgia.

19. The method of claim 18 , for treating cataplexy in narcoleptic patients.

20. The method of claim 19 , wherein said flecainide is the R enantiomer of formula:

21. The method of claim 2 wherein the flecainide and modafinil are administered simultaneously, separately or in a staggered manner.

22. The method of claim 18 wherein the flecainide and modafinil are administered simultaneously, separately or in a staggered manner.

Assignees

• Commissariat Energie Atomique

Inventors

• Mouthon Franck
• Charveriat Mathieu

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P25/06

  Antimigraine agents · CPC title

• A61P25/20

  Hypnotics; Sedatives · CPC title